

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jose Luis Castro Pineiro

Serial No.: 10/789,008

Case No.: T1591

Filed: February 27, 2004

For: METHOD AND MATERIALS FOR TREATMENT OF
ALZHEIMER'S DISEASE

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22131-1450


SUBMITTAL OF PRIORITY DOCUMENTS

Sir:

Enclosed please find a certified copy of the following priority document for
submittal with respect to the above-noted application:

Foreign Application - Great Britain 0304524.2 filed 2/27/2003


Respectfully submitted,

By 
John C. Todaro, Reg. No. 36,036
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0125

Date: March 31, 2004

**I hereby certify that this correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450,
Alexandria, Virginia 22131-1450, on the date
appearing below.**

By 
MERCK & CO., INC.
Date 3-31-04



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

ERICKSON, W.C.



INVESTOR IN PEOPLE


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 25 February 2004




The
Patent
Office

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

27 FEB 2003

1. Your reference

T1591PV

28FEB03 E788459-1 002639

P0177700 0.00-0304524.2

2. Patent application number

(The Patent Office will fill in this part)

0304524.2

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

Patents ADP number (if you know it)

00597799001

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

Therapeutic agents

5. Name of your agent (if you have one)

Dr. W. G. Cole

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Merck & Co., Inc.
European Patent Department
Terlings Park
Eastwick Road
Harlow
Essex CM20 2QR

Patents ADP number (if you know it)

01010289001

4448791001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority Application number
(if you know it)

Date of filing
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	0
Description	17
Claim(s)	0
Abstract	0
Drawing(s)	0

10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	-
Request for substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	-

11.

I/We request the grant of a patent on the basis of this application.

Signature

Dr. W. G. Cole

Date 26 February 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr. W. G. Cole

01279 440163

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

THERAPEUTIC AGENTS

The present invention relates to a novel method of treating Alzheimer's disease, and to novel compounds, their salts and pharmaceutical compositions comprising them suitable for use the said method. In particular, the invention relates to methods for the treatment or prevention of Alzheimer's disease which combine nitric oxide release with the inhibition of the formation or release of β -amyloid.

Alzheimer's disease (AD) is the most prevalent form of dementia. Although primarily a disease of the elderly, affecting up to 10% of the population over the age of 65, AD also affects significant numbers of younger patients with a genetic predisposition. It is a neurodegenerative disorder, clinically characterized by progressive loss of memory and cognitive function, and pathologically characterized by the deposition of extracellular proteinaceous plaques in the cortical and associative brain regions of sufferers. These plaques mainly comprise fibrillar aggregates of β -amyloid peptide ($A\beta$). The role of secretases, including the putative γ -secretase, in the processing of amyloid precursor protein (APP) to form $A\beta$ is well documented in the literature and is reviewed, for example, in WO 01/70677.

One approach to the treatment or prevention of Alzheimer's disease involves inhibition of the formation or release of $A\beta$, e.g by inhibition of one or more of the secretases, in particular γ -secretase. Compounds which inhibit γ -secretase are disclosed in WO 01/53255, WO 01/66564, WO 01/70677, WO 01/90084, WO 01/77144, WO 02/30912, WO 02/36555, WO 02/081435 and WO 02/081433. Other compounds which inhibit the formation or release of $A\beta$ include those disclosed in WO 98/28268, WO 02/47671, WO 99/67221, WO 01/34639, WO 01/34571, WO 00/07995, WO 00/38618, WO 01/92235, WO 01/77086, WO 01/74784, WO 01/74796, WO 01/74783, WO 01/60826, WO 01/19797, WO 01/27108, WO 01/27091, WO 00/50391, WO 02/057252, US 2002/0025955 and US2002/0022621.


An alternative approach to the treatment of Alzheimer's disease involves administering anti-inflammatory agents (especially NSAIDs) with a view to counteracting the neurotoxic effects of secreted A β .

According to several reports (e.g. Jantzen et al, *J. Neuroscience*, 2002, 26, 2246-54; Wenk et al, *Eur. J. Pharmacol.*, 2002, 453, 319-24; and WO 02/092072), improved results are obtained using NSAIDs which are capable of releasing nitric oxide (NO) subsequent to administration.

According to the present invention there is provided a method for the treatment or prevention of Alzheimer's disease comprising administering to a subject in need thereof a therapeutically-effective amount of a compound which inhibits the formation or release of β -amyloid and a therapeutically-effective amount of a nitric oxide releaser.

Any compound known to release NO subsequent to administration to a human or animal subject may be used in the invention. Such compounds are well known in the art, and are typically nitrate esters of alkanols. Likewise, any of the known inhibitors of the formation or release of A β may be used, such as the compounds disclosed in WO 01/53255, WO 01/66564, WO 01/70677, WO 01/90084, WO 01/77144, WO 02/30912, WO 02/36555, WO 02/081435, WO 02/081433, WO 98/28268, WO 02/47671, WO 99/67221, WO 01/34639, WO 01/34571, WO 00/07995, WO 00/38618, WO 01/92235, WO 01/77086, WO 01/74784, WO 01/74796, WO 01/74783, WO 01/60826, WO 01/19797, WO 01/27108, WO 01/27091, WO 00/50391, WO 02/057252, US 2002/0025955 and US2002/0022621.

Preferably said inhibitor and said nitric oxide releaser are administered simultaneously, and advantageously said inhibitor and said nitric oxide releaser are combined in a single dosage formulation, or are one and the same chemical compound. Such a chemical compound is typically a compound of formula I:




I

where R is such that R-CH₂OH or R-CHO is an inhibitor of the formation or release of A β ;
or a pharmaceutically acceptable salt thereof.

R may be such that R-CH₂OH or R-CHO belongs to any of the
5 classes of inhibitor disclosed in the above-listed patent applications, but preferably R-CH₂OH or R-CHO is a γ -secretase inhibitor, e.g. of the type disclosed in WO 02/36555 or WO 02/081435.

The invention also extends to novel compounds, suitable for use in
the above method, which combine NO-releasing activity with a capability
10 for γ -secretase inhibition. In particular, there is provided a compound of formula II:



wherein:

- m is 0 or 1;
- 15 n is 0 or 1;
- p is an integer in the range 1-6;
- L is a linking group;
- R¹ᵇ represents H, C₁₋₄alkyl or OH;
- R¹ᶜ represents H or C₁₋₄alkyl;
- 20 Ar¹ and Ar² independently represent phenyl or heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, CHO, CH=NOH, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₂₋₆acyl, C₂₋₆alkenyl and C₁₋₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and
- 25 C₁₋₄alkoxy;
- or a pharmaceutically acceptable salt thereof.

As used herein, the expression "hydrocarbon group" refers to groups consisting solely of carbon and hydrogen atoms. Such groups may comprise linear, branched or cyclic structures, singly or in any combination consistent with the indicated maximum number of carbon atoms, and may be saturated or unsaturated, including aromatic when the indicated maximum number of carbon atoms so permits.

As used herein, the expression " C_{1-x} alkyl" where x is an integer greater than 1 refers to straight-chained and branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to x. Particular alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl. Derived expressions such as " C_{2-6} alkenyl", "hydroxy C_{1-6} alkyl", "heteroaryl" C_{1-6} alkyl, " C_{2-6} alkynyl" and " C_{1-4} alkoxy" are to be construed in an analogous manner.

The expression " C_{6-10} aryl" as used herein includes phenyl and naphthyl. Phenyl is preferred.

The expression "heteroaryl" as used herein means a cyclic or polycyclic system of up to 10 ring atoms selected from C, N, O and S, wherein at least one of the constituent rings is aromatic and comprises at least one ring atom which is other than carbon. Where a heteroaryl ring comprises two or more atoms which are not carbon, not more than one of said atoms may be other than nitrogen. Preferred heteroaryl groups contain 5 or 6 ring atoms in total. Examples of heteroaryl groups include pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furyl, thienyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, oxadiazolyl, triazolyl and thiadiazolyl groups and benzo-fused analogues thereof. Further examples of heteroaryl groups include tetrazole, 1,2,4-triazine and 1,3,5-triazine.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred.

For use in medicine, the compounds of formula II may advantageously be in the form of pharmaceutically acceptable salts. Other

salts may, however, be useful in the preparation of the compounds of formula II or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, benzenesulphonic acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Alternatively, where the compounds of the invention carry an acidic moiety, pharmaceutically acceptable salts may be formed by neutralisation of said acidic moiety with a suitable base. Examples of pharmaceutically acceptable salts thus formed include alkali metal salts such as sodium or potassium salts; ammonium salts; alkaline earth metal salts such as calcium or magnesium salts; and salts formed with suitable organic bases, such as amine salts (including pyridinium salts) and quaternary ammonium salts.

Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.

In the compounds of formula II, m and n are independently 0 or 1, but m is preferably 1. Suitable values for p are in the range 1-6, especially 3-5, and most preferably p is 4.


L (when present) represents a bivalent linking group, typically comprising up to 20 (preferably up to 15) skeletal atoms selected from carbon and oxygen. In one embodiment, L comprises an optionally-substituted hydrocarbon residue linked to the $-(CH_2)_nONO_2$ moiety by an ester group, and may be represented by the formula:



wherein L^1 is a hydrocarbon residue of up to 10 carbon atoms, optionally bearing up to 3 substituents selected from halogen, CN, OH and C_{1-4} alkoxy. In a preferred embodiment, L^1 represents:



- 5 wherein Ar is a phenyl group bearing up to 2 substituents selected from hydroxy and methoxy. In a particularly preferred embodiment, L represents:



- 10 R^{1c} represents H or C_{1-4} alkyl, such as methyl or ethyl, but preferably represents H.

R^{1b} represents H, C_{1-4} alkyl or OH, but preferably represents H.


In a particular embodiment, m is 1 and R^{1b} and R^{1c} are both H.

- 15 Ar^1 and Ar^2 independently represent optionally-substituted phenyl or heteroaryl. Typical heteroaryl embodiments of Ar^1 include optionally substituted pyridyl, in particular optionally substituted 3-pyridyl. Ar^1 is preferably selected from 5-(trifluoromethyl)-3-pyridyl and phenyl which is optionally substituted in the 4-position with halogen, CN, vinyl, allyl, acetyl, methyl or mono-, di- or trifluoromethyl. In one preferred embodiment of the invention Ar^1 is selected from 4-chlorophenyl, 4-trifluoromethylphenyl and 5-(trifluoromethyl)-3-pyridyl.

- 20 Ar^2 preferably represents phenyl bearing at least one substituent as defined previously, in particular phenyl bearing 2 or 3 substituents selected from halogen, CN, CF_3 and optionally-substituted alkyl. Ar^2 is typically selected from phenyl groups bearing halogen substituents (preferably fluorine) in the 2- and 5- positions, in the 2- and 6-positions or in the 2-, 3- and 6-positions, or from phenyl groups bearing a fluorine substituent in the 2-position and halogen, CN, methyl or hydroxymethyl in the 5-position. In a preferred embodiment of the invention, Ar^2 represents 2,5-difluorophenyl, 2,6-difluorophenyl or 2,3,6-trifluorophenyl.


In a particular embodiment, Ar¹ is 4-chlorophenyl or 4-trifluoromethylphenyl and Ar² is 2,5-difluorophenyl.

Examples of compounds in accordance with the invention include:



5

and



and pharmaceutically acceptable salts thereof.

10 The compounds of the present invention have an activity as inhibitors of γ secretase.

The invention also provides pharmaceutical compositions comprising one or more compounds of formula II (or pharmaceutically acceptable salts thereof) and a pharmaceutically acceptable carrier.

15 Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for

administration by inhalation or insufflation. The principal active ingredient typically is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate and dicalcium phosphate, or gums, dispersing agents, suspending agents or surfactants such as sorbitan monooleate and polyethylene glycol, and other pharmaceutical diluents, e.g. water, to form a homogeneous preformulation composition containing a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 250 mg, for example 5, 10, 25, 50, 100 or 200 mg, of the active ingredient. Tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, liquid- or gel-filled capsules, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible

oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium
5 carboxymethylcellulose, methylcellulose, poly(ethylene glycol), poly(vinylpyrrolidone) or gelatin.

The present invention also provides a compound of formula II or a pharmaceutically acceptable salt thereof for use in a method of treatment of the human body. Preferably the treatment is for a condition associated
10 with the deposition of β -amyloid. Preferably the condition is a neurological disease having associated β -amyloid deposition such as Alzheimer's disease.


The present invention further provides the use of a compound of formula II or a pharmaceutically acceptable salt thereof in the
15 manufacture of a medicament for treating or preventing Alzheimer's disease.

Also disclosed is a method of treatment of a subject suffering from or prone to Alzheimer's disease which comprises administering to that subject an effective amount of a compound of formula II or a
20 pharmaceutically acceptable salt thereof.

For treating or preventing Alzheimer's disease, the optimum dosage level of the compounds of formula II, in terms of safety and efficacy, may vary according to the severity of the disease and/or other factors specific to the individual patient, and may be determined by methods well known to
25 those skilled in the art. Generally speaking, doses of about 0.1 to 250 mg/kg per day, preferably about 0.5 to 100 mg/kg per day, more preferably about 1 to 50 mg/kg of body weight per day, may be contemplated. The compounds may be administered on any suitable regimen, for example 1 to 4 times per day. However, other regimens and/or dosage levels outside the
30 limits outlined above may be used if circumstances so demand.


For treatment or prevention of Alzheimer's disease by administration of prior art compounds which are modified so as to release NO or which are administered in combination with a separate NO-releaser, suitable dosage levels and frequencies will be in line with the values recommended for the unmodified compounds in question, used alone.

Compounds of formula II may be prepared by reaction of a compound of formula III with silver nitrate:



where X represents chlorine, bromine or iodine, and m, n, p, L, R^{1b}, R^{1c}, Ar¹ and Ar² have the same meanings as before. The reaction takes place in refluxing acetonitrile with protection from light.

Compounds of formula III may be prepared by coupling of acids IV with HO-(L)_n-(CH₂)_p-X:



where X, m, n, p, L, R^{1b}, R^{1c}, Ar¹ and Ar² have the same meanings as before. Any of the known techniques of esterification may be used, such as conversion of acids IV to the corresponding acid chlorides prior to treatment with the relevant hydroxy compound in the presence of base.

Compounds of formula III in which n is 1 and L is -L¹-C(O)O- may alternatively be prepared by esterifying an acid IV with HO-L¹-CO₂H, then esterifying the product with HO-(CH₂)_p-X, where L¹ and X have the same meanings as before.

The acids IV may be prepared as described in WO 02/081435.

It will be appreciated by those skilled in the art that a given compound in accordance with formula II may be converted into another compound also in accordance with formula I by means of standard synthetic techniques such as alkylation, oxidation, reduction,
5 esterification, amide coupling, hydrolysis, electrophilic substitution and nucleophilic substitution. Alternatively, such conversions may be carried out on synthetic precursors of the compounds of formula II.

It will also be appreciated that where more than one isomer can be obtained from a reaction then the resulting mixture of isomers can be
10 separated by conventional means.

Where the above-described process for the preparation of the compounds according to the invention gives rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The novel compounds may be
15 prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such
20 as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid, followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, such techniques may be carried out on
25 racemic synthetic precursors of the compounds of interest.

Where they are not commercially available, the starting materials and reagents used in the above-described synthetic schemes may be prepared by conventional means.

During any of the above synthetic sequences it may be necessary
30 and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional

protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

An assay which can be used to determine the level of activity of compounds of the present invention is described in WO01/70677. A preferred assay to determine such activity is as follows:

- 1) SH-SY5Y cells stably overexpressing the β APP C-terminal fragment SPA4CT, are cultured at 50-70% confluency. 10mM sodium butyrate is added 4 hours prior to plating.
- 2) Cells are plated in 96-well plates at 35,000 cells/well/100 μ L in Dulbeccos minimal essential medium (DMEM) (phenol red-free) + 10% foetal bovine serum (FBS), 50mM HEPES buffer (pH7.3), 1% glutamine.
- 3) Make dilutions of the compound plate. Dilute stock solution 18.2x to 5.5% DMSO and 11x final compound concentration. Mix compounds vigorously and store at 4°C until use.
- 4) Add 10 μ L compound/well, gently mix and leave for 18h at 37°C, 5% CO₂.
- 5) Prepare reagents necessary to determine amyloid peptide levels, for example by Homogeneous Time Resolved Fluorescence (HTRF) assay.
- 6) Plate 160 μ L aliquots of HTRF reagent mixture to each well of a black 96-well HTRF plate.
- 7) Transfer 40 μ L conditioned supernatant from cell plate to HTRF plate. Mix and store at 4°C for 18 hours.
- 8) To determine if compounds are cytotoxic following compound administration, cell viability is assessed by the use of redox dye reduction. A typical example is a combination of redox dye MTS (Promega) and the electron coupling reagent PES. This mixture is made up according to the manufacturer's instructions and left at room temperature.

9) Add 10 μ L/well MTS/PES solution to the cells; mix and leave at 37°C.

10) Read plate when the absorbance values are approximately 0.4 – 0.8. (Mix briefly before reading to disperse the reduced formazan product).

5 11) Quantitate amyloid beta 40 peptide using an HTRF plate reader. Alternative assays are described in *Biochemistry*, 2000, 39(30), 8698-8704.


See also, *J. Neuroscience Methods*, 2000, 102, 61-68.

10 The compounds of the present invention generally show high potency as measured by the above assays. Thus the following Examples all had an ED₅₀ of less than 1 μ M, typically less than 250nM, and frequently less than 100nM in at least one of the above assays.

The following examples illustrate the present invention.

15 **Example 1.** Cis 4-(nitrooxy)butyl 3-(4-(2,5-difluorophenyl)-4-[[4(trifluoromethyl) phenyl]sulfonyl]cyclohexyl)propanoate

Step 1: Cis-4-bromobutyl 3-(4-(2,5-difluorophenyl)-4-[[4-(trifluoromethyl) phenyl]sulfonyl]cyclohexyl)propanoate




20

Sodium hydride (60% dispersion in oil, 32mg, 0.8 mmol) was added to a stirred solution of cis-3-(4-(2,5-difluorophenyl)-4-[[4-(trifluoromethyl) phenyl]sulfonyl]cyclohexyl)propanoic acid (300mg, 0.63 mmol) (prepared by the methods disclosed in WO 02/081435) in dry DMF (5mL) at room temperature under nitrogen. After 90 minutes, 1,4-dibromobutane (150 μ L, 1.3 mmol) was added. After stirring at room temperature overnight the reaction was quenched with water. The mixture was extracted with ethyl

25

5 ([M+Na]⁺), 613 ([MH]⁺), 611 ([MH]⁺).


Step 2: Cis 4-(nitrooxy)butyl 3-(4-(2,5-difluorophenyl)-4-
[[4(trifluoromethyl) phenyl]sulfonyl]cyclohexyl)propanoate



A mixture of the bromide from Step 1 (300mg, 0.49 mmol) and silver nitrate (170mg, 1.0 mmol) in dry acetonitrile (5 mL) was stirred and heated at reflux, protected from light, for two hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and filtered. The filtrate was evaporated and purified by chromatography on silica, eluting with 10 to 20 to 40% ethyl acetate/hexanes to give the title compound (217mg, 75%) as an oil. δ (^1H , 360MHz, CDCl_3) 1.43-1.62 (3H, m), 1.68-1.89 (8H, m), 2.30-2.52 (6H, m), 4.12 (2H, t, $J=6.1$), 4.50 (2H, t, $J=6.1$), 6.76-6.84 (1H, m), 7.00-7.10 (2H, m), 7.53 (2H, d, $J=8.2$), 7.65 (2H, d, $J=8.2$); MS (ES+) 616 ($[\text{M}+\text{Na}]^+$).

Example 2. Cis-4-(nitrooxy)butyl (2E)-3-(4-([3-(4-(2,5-difluorophenyl)-4-
 {[4-(trifluoromethyl)phenyl]sulfonyl}cyclohexyl)propanoyl]oxy)-3-
 methoxyphenyl)prop-2-enoate


5 **Step 1:** Cis-4-bromobutyl (2E)-3-(4-([3-(4-(2,5-difluorophenyl)-4-
 (trifluoromethyl)phenyl]sulfonyl}cyclohexyl)propanoyl]oxy)-3-
 methoxyphenyl)prop-2-enoate



N,N-Dimethylformamide (1 drop) was added to a stirred solution of cis-3-
 10 (4-(2,5-difluorophenyl)-4-([4-(trifluoromethyl)phenyl]sulfonyl}cyclohexyl)
 propanoic acid (300mg, 0.63 mmol) and oxalyl chloride (120 μ L, 1.4 mmol)
 in dry dichloromethane (5 mL) at room temperature. After two hours at
 room temperature, the volatiles were removed *in vacuo*. The residue was
 taken up in dry dichloromethane (2 mL) under nitrogen. 4-Hydroxy-3-
 15 methoxycinnamic acid (120mg, 0.63 mmol) and then pyridine (250 μ L, 3:1
 mmol) were added. The mixture was stirred at room temperature
 overnight, then quenched with methanol (5 mL). The volatiles were
 removed *in vacuo*. The residue was partitioned between ethyl acetate and
 hydrochloric acid (1N). The aqueous layer was extracted with ethyl acetate
 20 (x2). The combined organic extracts were washed with brine (x1), then
 dried (Na_2SO_4), filtered and evaporated. Partial purification by
 chromatography on silica, eluting with 50% ethyl acetate/hexanes + 1%
 acetic acid gave the crude cinnamic acid (387mg). This material was used
 without further purification.
 25 Sodium hydride (60% dispersion, 32 mg, 0.8 mmol) was added to a stirred
 solution of the crude acid from above (329 mg) in dry DMF (2 mL) at room

temperature under nitrogen. After two hours 1,4-dibromobutane (150 μ L, 1.3 mmol) was added. The mixture was stirred at room temperature overnight, then quenched with water and extracted with ethyl acetate (x3). The combined extracts were washed with brine (x1), dried (Na_2SO_4),
 5 filtered and evaporated. The residue was purified by chromatography on silica, eluting with 10% to 20% to 30% ethyl acetate/hexanes to give the bromide (123 mg, 25% over 2 steps) as an oil. δ (^1H , 400MHz, CDCl_3) 1.49-1.59 (2H, m), 1.68-2.05 (9H, m), 2.40-2.55 (4H, m), 2.62 (2H, t, $J=7.6$), 3.47 (2H, t, $J=6.6$), 3.86 (3H, s), 4.25 (2H, t, $J=6.3$), 6.38 (1H, d, $J=16.0$), 6.78-
 10 6.84 (1H, m), 7.02-7.15 (5H, m), 7.54 (2H, d, $J=8.2$), 7.62-7.67 (3H, m); MS (ES+) 789 ($[\text{MH}]^+$), 787 ($[\text{MH}]^+$).

Step 2: 4-(nitrooxy)butyl (2E)-3-(4-([3-(4-(2,5-difluorophenyl)-4-([4-(trifluoromethyl)phenyl]sulfonyl)cyclohexyl)propanoyl]oxy)-3-methoxyphenyl)prop-2-enoate
 15



A mixture of the bromide from step 1 (105 mg, 0.13 mmol) and silver nitrate (45mg, 0.26 mmol) in dry acetonitrile (1 mL) was stirred and heated at reflux under nitrogen, protected from light, for two hours. After
 20 cooling to room temperature the mixture was diluted with ethyl acetate and filtered. The filtrate was evaporated. The residue was purified by chromatography, eluting with 10% to 20% to 30% ethyl acetate/ hexanes to give desired product (92 mg, 92%) as a foam. δ (^1H , 400MHz, CDCl_3) 1.50-1.60 (2H, m), 1.68-1.99 (9H, m), 2.40-2.55 (4H, m), 2.62 (2H, t, $J=7.6$), 3.86
 25 (3H, s), 4.26 (2H, t, $J=5.9$), 4.53 (2H, t, $J=6.1$), 6.38 (1H, d, $J=16.0$), 6.79-

6.84 (1H, m), 7.03-7.14 (5H, m), 7.54 (2H, d, J=8.2), 7.63-7.67 (3H, m); MS (ES+) 770 ([MH]⁺).

5

10

